Two vaccine trials are opening up in Texas for early stage Her2 patients. You must currently be NED, at high risk for recurrence and within 6 months of your last active treatment (including herceptin) to enroll. (At least that is my understanding.) The trial at MD Anderson is a phase 2 trial of a single peptide (I think)....You may be randomized to a non-vaccine arm if you enroll in the MD Anderson trial.
The trial that is opening at the Mary Crowley Cancer Center in Dallas is a phase 1 trial and involves multiple peptides for the vaccine. Since it is a phase 1 trial they are studying safety among other things so you may not receive what will prove to be the optimal dose of the vaccine. You will get some of the vaccine in any case.
If you are interested in these trials, please contact either Dr. Mittendorf (if you want more info on the MD Anderson trial) or Neil Senzer if you are interested in the Mary Crowly phase I trial. I am in no position to vouch for the accuracy of the statements in this email as I am summarizing my understanding of each trial but I am not an expert.
The below email is from Dr. Elizabeth Mittendorf at MD Anderson:
"It appears that the phase 1 trial looking at the multiepitope vaccine will launch at the Mary Crowley cancer center at the end of this month or early Aug. The point of contact is as follows:
POC Neil Senzer…
nsenzer@marycrowley.org
We are anticipating that we will launch the phase II trial here at MDACC around the same time.
Please keep me posted as to how you would like to proceed and let me know if I can provide you with additional information. "
Beth
Elizabeth A. Mittendorf, M.D.
Assistant Professor
Department of Surgical Oncology
U. T. M.D. Anderson Cancer Center
1515 Holcombe Blvd. Unit 444
Houston, TX 77030
eamitten@mdanderson.org
Threaded Mode